No quarterly revenue total was found in BlossomHill Therapeutics, Inc.'s SEC filings.
BlossomHill Therapeutics, Inc. (BLSM) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$44.2 million. As of Jun 30, 2026 it held $95.4 million in cash and investments and $1.1 million in total debt.
Revenue
—
Net income
$-23.76M
Operating cash flow
$-44.17M
Free cash flow
$-44.19M
EPS
$-8.75
Dividend per share
None
Shares outstanding
31.78M
Net cash
$94.23M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BLSM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1839970
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Operating income | -$24.7M |
| Net income | -$23.8M |
| Diluted EPS | -$8.75 |
| Operating cash flow | -$44.2M |
| Free cash flow | -$44.2M |
| Total assets | $124.1M |
| Total liabilities | $42.1M |
| Stockholders' equity | -$174.8M |
| Cash and investments | $95.4M |
| Total debt | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 18, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
All 44 BlossomHill Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.